Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of ABBV-951 in Parkinson's Disease
NCT04379050Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2020
- Primary completion
- Apr 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of foscarbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc.. Started Jun 2020; status: completed.
02
Drugs
foscarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04379050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04379050.